Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 3, 2015, Pages 273-279

  Kuhle, Jens ^a,b   Gaiottino, Johanna ^a   Leppert, David ^b   Petzold, Axel ^c   Bestwick, Jonathan P ^a   Malaspina, Andrea ^a,d   Lu, Ching Hua ^a   Dobson, Ruth ^a   Disanto, Giulio ^a   Norgren, Niklas ^e   Nissim, Ahuva ^f   Kappos, Ludwig ^b   Hurlbert, John ^g   Yong, V Wee ^g   Giovannoni, Gavin ^a   Casha, Steven ^g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d North East London and Essex MND Care and Research Centre   (United Kingdom)

^e UmanDiagnostics AB   (Sweden)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MINOCYCLINE; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; PLACEBO; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN L;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINAL CORD INJURY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SPINAL CORD INJURIES;

ADULT; ANTI-BACTERIAL AGENTS; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINOCYCLINE; NEUROFILAMENT PROTEINS; NEUROLOGIC EXAMINATION; PROGNOSIS; REFERENCE VALUES; SPINAL CORD INJURIES;

EID: 84923187687     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-307454     Document Type: Article

References (34)

1. Maier IC, Schwab ME. Sprouting, regeneration and circuit formation in the injured spinal cord: factors and activity. Philos Trans R Soc Lond B Biol Sci 2006;361:1611-34.
2. Kwon BK, Tetzlaff W, Grauer JN, et al. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004;4:451-64.
3. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26.
4. Yong VW, Wells J, Giuliani F, et al. The promise of minocycline in neurology. Lancet Neurol 2004;3:744-51.
5. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90.
6. Courtine G, Bunge MB, Fawcett JW, et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat Med 2007;13:561-6.
7. Casha S, Zygun D, McGowan MD, et al. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 2012;135:1224-36.
8. Ditunno JF Jr., Young W, Donovan WH, et al. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994;32:70-80.
9. Fawcett JW, Curt A, Steeves JD, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007;45:190-205.
10. Kwon BK, Casha S, Hurlbert RJ, et al. Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin Chem Lab Med 2011;49:425-33.
11. Kuhle J, Petzold A. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases. Expert Opin Med Diagn 2011;5:333-46.
12. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013;8: e75091.
13. Harrop JS, Sharan A, Ratliff J. Central cord injury: pathophysiology, management, and outcomes. Spine J 2006;6:198S-206S.
14. Petzold A, Keir G, Green AJ, et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-90.
15. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-98.
16. Petzold A, Tisdall MM, Girbes AR, et al. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain 2011;134:464-83.
17. Zetterberg H, Smith DH, Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 2013;9:201-10.
18. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-6.
19. Sadowsky C, Volshteyn O, Schultz L, et al. Spinal cord injury. Disabil Rehabil 2002;24:680-7.
20. Hayakawa K, Okazaki R, Ishii K, et al. Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord 2012;50:493-6.
21. Guez M, Hildingsson C, Rosengren L, et al. Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. J Neurotrauma 2003;20:853-8.
22. Shaw G, Yang C, Ellis R, et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005;336:1268-77.
23. Ueno T, Ohori Y, Ito J, et al. Hyperphosphorylated neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury. Spinal Cord 2011;49:333-6.
24. Geisler FH, Coleman WP, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976) 2001;26:S87-98.
25. Tator CH. Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 2006;59:957-82.
26. Fehlings MG, Baptiste DC. Current status of clinical trials for acute spinal cord injury. Injury 2005;36(Suppl 2):B113-22.
27. Lammertse DP. Update on pharmaceutical trials in acute spinal cord injury. J Spinal Cord Med 2004;27:319-25.
28. Fawcett JW. Novel strategies for protection and repair of the central nervous system. Clin Med 2006;6:598-603.
29. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-26.
30. Lee SM, Yune TY, Kim SJ, et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003;20:1017-27.
31. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-90.
32. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 2004;101:3071-6.
33. Wells JE, Hurlbert RJ, Fehlings MG, et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003;126:1628-37.
34. Popovic N, Schubart A, Goetz BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002;51:215-23.